148 related articles for article (PubMed ID: 11769819)
1. Comparison between noradrenergic and serotonergic medications using the social adjustment scale: is drive enhancement necessary for recovery of social functioning?
Luty SE; Joyce PR; Mulder RT
J Psychopharmacol; 2001 Dec; 15(4):257-64. PubMed ID: 11769819
[TBL] [Abstract][Full Text] [Related]
2. Noradrenaline-selective versus serotonin-selective antidepressant therapy: differential effects on social functioning.
Dubini A; Bosc M; Polin V
J Psychopharmacol; 1997; 11(4 Suppl):S17-23. PubMed ID: 9438229
[TBL] [Abstract][Full Text] [Related]
3. Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke: a placebo-controlled, double-blind study.
Robinson RG; Schultz SK; Castillo C; Kopel T; Kosier JT; Newman RM; Curdue K; Petracca G; Starkstein SE
Am J Psychiatry; 2000 Mar; 157(3):351-9. PubMed ID: 10698809
[TBL] [Abstract][Full Text] [Related]
4. Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study.
Nelson JC; Mazure CM; Jatlow PI; Bowers MB; Price LH
Biol Psychiatry; 2004 Feb; 55(3):296-300. PubMed ID: 14744472
[TBL] [Abstract][Full Text] [Related]
5. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease.
Roose SP; Laghrissi-Thode F; Kennedy JS; Nelson JC; Bigger JT; Pollock BG; Gaffney A; Narayan M; Finkel MS; McCafferty J; Gergel I
JAMA; 1998 Jan; 279(4):287-91. PubMed ID: 9450712
[TBL] [Abstract][Full Text] [Related]
6. A differential response to nortriptyline and fluoxetine in melancholic depression: the importance of age and gender.
Joyce PR; Mulder RT; Luty SE; McKenzie JM; Rae AM
Acta Psychiatr Scand; 2003 Jul; 108(1):20-3. PubMed ID: 12807373
[TBL] [Abstract][Full Text] [Related]
7. Patterns and predictors of remission, response and recovery in major depression treated with fluoxetine or nortriptyline.
Joyce PR; Mulder RT; Luty SE; Sullivan PF; McKenzie JM; Abbott RM; Stevens IF
Aust N Z J Psychiatry; 2002 Jun; 36(3):384-91. PubMed ID: 12060188
[TBL] [Abstract][Full Text] [Related]
8. Reboxetine versus fluoxetine: an overview of efficacy and tolerability.
Massana J
J Clin Psychiatry; 1998; 59 Suppl 14():8-10. PubMed ID: 9818624
[TBL] [Abstract][Full Text] [Related]
9. Augmentation strategies with serotonergic-noradrenergic combinations.
Nelson JC
J Clin Psychiatry; 1998; 59 Suppl 5():65-8; discussion 69. PubMed ID: 9635550
[TBL] [Abstract][Full Text] [Related]
10. Double-blind comparison of fluoxetine and nortriptyline in the treatment of moderate to severe major depression.
Akhondzadeh S; Faraji H; Sadeghi M; Afkham K; Fakhrzadeh H; Kamalipour A
J Clin Pharm Ther; 2003 Oct; 28(5):379-84. PubMed ID: 14632962
[TBL] [Abstract][Full Text] [Related]
11. Atypical depression, atypical temperament and a differential antidepressant response to fluoxetine and nortriptyline.
Joyce PR; Mulder RT; McKenzie JM; Luty SE; Cloninger CR
Depress Anxiety; 2004; 19(3):180-6. PubMed ID: 15129420
[TBL] [Abstract][Full Text] [Related]
12. Do noradrenaline and serotonin differentially affect social motivation and behaviour?
Dubini A; Bosc M; Polin V
Eur Neuropsychopharmacol; 1997 Apr; 7 Suppl 1():S49-55; discussion S71-3. PubMed ID: 9169310
[TBL] [Abstract][Full Text] [Related]
13. A comparison of effects of fluoxetine and nortriptyline on the symptoms of major depressive disorder.
Mowla A; Ghanizadeh A; Pani A
J Clin Psychopharmacol; 2006 Apr; 26(2):209-11. PubMed ID: 16633155
[No Abstract] [Full Text] [Related]
14. Long-term outcomes of initial antidepressant drug choice in a "real world" randomized trial.
Simon GE; Heiligenstein J; Revicki D; VonKorff M; Katon WJ; Ludman E; Grothaus L; Wagner E
Arch Fam Med; 1999; 8(4):319-25. PubMed ID: 10418538
[TBL] [Abstract][Full Text] [Related]
15. Tryptophan and tyrosine availability and response to antidepressant treatment in major depression.
Porter RJ; Mulder RT; Joyce PR; Luty SE
J Affect Disord; 2005 Jun; 86(2-3):129-34. PubMed ID: 15935231
[TBL] [Abstract][Full Text] [Related]
16. Relationships among measures of treatment outcome in depressed patients.
Mulder RT; Joyce PR; Frampton C
J Affect Disord; 2003 Sep; 76(1-3):127-35. PubMed ID: 12943942
[TBL] [Abstract][Full Text] [Related]
17. Norepinephrine involvement in antidepressant action.
Frazer A
J Clin Psychiatry; 2000; 61 Suppl 10():25-30. PubMed ID: 10910014
[TBL] [Abstract][Full Text] [Related]
18. Poststroke depression.
Franco K; Malhotra S
Am J Psychiatry; 2001 Apr; 158(4):658-60. PubMed ID: 11282720
[No Abstract] [Full Text] [Related]
19. Preventing poststroke depression: a 12-week double-blind randomized treatment trial and 21-month follow-up.
Narushima K; Kosier JT; Robinson RG
J Nerv Ment Dis; 2002 May; 190(5):296-303. PubMed ID: 12011609
[TBL] [Abstract][Full Text] [Related]
20. Melancholia: definitions, risk factors, personality, neuroendocrine markers and differential antidepressant response.
Joyce PR; Mulder RT; Luty SE; McKenzie JM; Sullivan PF; Abbott RM; Stevens IF
Aust N Z J Psychiatry; 2002 Jun; 36(3):376-83. PubMed ID: 12060187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
